Senior Vice President, Program and Portfolio Strategy and Medical Affairs

Homa Yeganegi serves as Senior Vice President, Program and Portfolio Strategy and Medical Affairs for Avenzo Therapeutics. She has more than 25 years of experience in global biopharmaceuticals, focusing in oncology, product strategy, program management and medical affairs.

Prior to Avenzo, Ms. Yeganegi served as Senior Vice President, Global Program Team Lead, Head of Medical Affairs and Site Head for Turning Point Therapeutics, where she responsible for the global submission plan for AUGTYROTM (repotrectinib) and leading the company’s post-merger integration with Bristol Myers Squibb. Prior Avenzo, Ms. Yeganegi has also held similar roles at Halozyme, Clovis Oncology, Exelixis and Onyx Pharmaceuticals.

She received her B.S. in Biology from the University of Tehran, Iran, her M.S. in Neuroanatomy from the University of Western Australia and is completing her Ph.D. in Health Sciences.